Den här översättningen är inte klar ännu. Den här sidan är just nu på engelska.

Gå till den engelska sidan

Cure My Disease

Don't miss your cure!

 Log in / Sign up

AI reads your Heart's electrical signals to predict failure years in advance

NCT ID NCT07519434

Knowledge-focused Sponsor: Shanghai Zhongshan Hospital Source: ClinicalTrials.gov ↗

What the study statuses mean

This study's is highlighted.

Recruitment status, easiest to join first

Recruiting now
This trial is taking on new participants right now.
Not yet recruiting
Registered, but not yet taking participants.
By invitation only
Not open to general applications. Only people the study team invites can take part.
Paused
Paused for now. It may or may not start again.
Ongoing
Running, but no longer taking on new participants.
Completed This study
The trial has finished. Results may not be published yet.
Stopped early
Stopped early, before it reached the end. That can be for many reasons, including safety.
Cancelled
Cancelled before anyone took part.

Expanded access (not trials)

Expanded access
Not a trial. This treatment can be requested outside a study, case by case, for people who qualify.
Expanded access (paused)
Not a trial. The treatment can normally be requested outside a study, but is unavailable right now.
Expanded access (ended)
Not a trial. The treatment could once be requested outside a study, but no longer can.
Approved
The treatment has been approved, so it is available normally rather than through this programme.

When the status isn't known

Details not published
The full record has not been published yet, so there is little to show here.
Status unknown
This status has not been confirmed recently, so it may be out of date.

First seen Jun 27, 2026 · Last updated Jun 27, 2026

Summary

This study tested whether artificial intelligence (AI) could predict a person's risk of developing a specific type of heart failure (HFrEF) up to 5 years in the future, using only a standard ECG. Researchers analyzed data from over 286,000 adults in China and the US. The goal was to create a simple, widely available tool to identify high-risk individuals before symptoms appear, allowing for earlier prevention or treatment.

This is an AI summary of the original study and may miss details. Read our disclaimer.

Study facts

What this study's own registry entry says, in plain language.

Participants

286,709 people

The number who actually took part.

Started

Feb 2014

Finished

Dec 2023

Lead sponsor

Other sponsor

The registry's catch-all category, for sponsors it does not file as a company, a government agency, or a research network.

Who can take part

This study's own entry requirements. Only the study team can say for certain whether you qualify.

Who is studied

Participants were derived from three independent cohorts, including Zhongshan Hospital, Shanghai Tenth People's Hospital, and Beth Israel Deaconess Medical Center. The study population included adult patients who underwent routine ECG and echocardiographic evaluation in real-world clinical settings.

Ages

18 years and older

Sex

Anyone

Healthy volunteers

Accepted

You do not need to have the condition being studied to take part.

Show the full entry requirements

Copied word for word from the study's registry entry, so the wording is the study team's rather than ours.

Inclusion Criteria: Adults aged ≥18 years Underwent standard 12-lead electrocardiography (ECG) Underwent transthoracic echocardiography with available LVEF measurement Availability of paired ECG-echocardiography data Data available for follow-up assessment Exclusion Criteria: Missing or incomplete ECG or echocardiography data Poor-quality ECG recordings unsuitable for analysis Missing key clinical variables required for model development

Get updates

Get notified about this study

Sign up to get updates when this study changes or when new studies for Cardiac remodeling are added.

Vår säkerhetsrekommendation!

Genom att skicka in godkänner du våra Användarvillkor

Conditions

The condition(s) this trial relates to.

heart failure left ventricular failure Ventricular Dysfunction, Left systolic heart failure prevention target

As listed by the trial registrant

The condition terms exactly as the trial's registrant entered them.

Cardiac remodeling Heart failure Heart failure with reduced ejection fraction Left ventricular dysfunction

Contacts and locations

Locations

  • Study site

    Shanghai, Shanghai Municipality, 200436, China

More trials for these conditions

Other studies related to the condition(s) this trial covers.